Vitiligo is an autoimmune disease that leads to disfiguring depigmented lesions of skin and mucosa. Although effective treatments are available for vitiligo, there are still some patients with poor responses to conventional treatment. Refractory vitiligo lesions are mostly located on exposed sites such as acral sites and lips, leading to significant life stress. Understanding the causes of refractory vitiligo and developing targeted treatments are essential to enhance vitiligo outcomes. In this review, we summarized recent treatment approaches and some potential methods for refractory vitiligo. Janus kinase inhibitors have shown efficacy in refractory vitiligo. A variety of surgical interventions and fractional carbon dioxide laser have been widely applied to combination therapies. Furthermore, melanocyte regeneration and activation therapies are potentially effective strategies. Patients with refractory vitiligo should be referred to psychological monitoring and interventions to reduce the potential pathogenic effects of chronic stress. Finally, methods for depigmentation and camouflage may be beneficial in achieving uniform skin color and improved quality of life. Our ultimate focus is to provide alternative options for refractory vitiligo and to bring inspiration to future research.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10794984PMC
http://dx.doi.org/10.3389/fimmu.2023.1294919DOI Listing

Publication Analysis

Top Keywords

refractory vitiligo
28
vitiligo
10
refractory
6
management refractory
4
vitiligo patient
4
patient current
4
current therapeutic
4
therapeutic strategies
4
strategies future
4
future options
4

Similar Publications

Recalcitrant Pediatric Facial Vitiligo Successfully Treated with Roflumilast Cream 0.3% Once Daily.

J Clin Aesthet Dermatol

January 2025

Dr. Warren and Ms. Sanchez are with Derm Texas in Dallas, Texas.

Vitiligo is an autoimmune disorder that causes melanocyte damage and pigment loss. The clinical presentation of vitiligo consists of patchy areas of lighter skin and results from a loss of functioning melanocytes and may be more visible in darker skin toned patients. Vitiligo affects approximately 2 percent of children and adolescents in the United States, with half of the affected cases undiagnosed.

View Article and Find Full Text PDF

Atopic dermatitis (AD) may sometimes be comorbid with vitiligo. However, these therapeutic agents are often slow acting and lead to various adverse effects, resulting in poor patient compliance. This report describes a 65-year-old male patient with refractory moderate-to-severe atopic dermatitis (AD) and generalized vitiligo.

View Article and Find Full Text PDF

Background: Refractory melasma remains a challenge in dermatology, necessitating the exploration of innovative treatments.

Aims: This study aims to evaluate the efficacy and safety of combining radiofrequency microneedling (RFM) with Cysteamine cream, applied both in-office and as a part of a home-care regimen, to treat refractory melasma.

Patients/methods: A vehicle-controlled, split-face trial was conducted on 30 Fitzpatrick skin types III and IV participants.

View Article and Find Full Text PDF

Background: The autologous non-cultured melanocyte-keratinocyte transplantation procedure (MKTP) has emerged as an effective treatment for various types of vitiligo and leukodermas. However, there is limited data on the long-term outcomes of the MKTP, especially in Thai patients.

Objective: To assess the long-term efficacy and safety of the MKTP in patients with vitiligo and other leukodermas.

View Article and Find Full Text PDF

The role of aryl hydrocarbon receptor agonists in the treatment of vitiligo.

Arch Dermatol Res

October 2024

Dermatology Service, Veterans Affairs New York Harbor Healthcare System, Brooklyn Campus, Brooklyn, NY, US.

Article Synopsis
  • * Ruxolitinib is the only FDA-approved medication for vitiligo but has serious side effects, highlighting the need for safer alternatives like aryl hydrocarbon receptor (AhR) agonists.
  • * Recent research shows that AhR agonists, particularly tapinarof, promote skin repigmentation and have a better safety profile, but more clinical trials are needed to fully assess their potential in vitiligo treatment.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!